连云港海恒生化科技有限公司

Lianyungang Haiheng Biochemical Technology Co., Ltd. was established in 2002 and is located in the Lianyungang Guanyun Port Industrial Park in Jiangsu Province. It is a production enterprise primarily engaged in the manufacturing of pharmaceutical active ingredients and their intermediates, as well as the technological development of new drugs. The company has its own research and development center, equipped with advanced testing instruments and experienced technical personnel. The company covers an area of 50 acres, with a planned total construction area of 50,000 square meters. Currently, the company employs 80 staff members, 40 of whom hold college degrees or higher, accounting for 50% of the total workforce.

 

The company currently operates a modern, multifunctional drug research and development center spanning over 1,000 square meters, located within a high-tech business incubator park, and has four production workshops for pharmaceutical intermediates. Since its inception, the company has successfully developed and promoted over sixty types of pharmaceutical intermediates, including health supplements, anti-tumor, anti-viral, cardiovascular, and novel antibiotic series. It has established long-term, stable collaborations with numerous renowned pharmaceutical companies both domestically and internationally in areas such as innovative drug research and development, technological achievement transformation, cooperative production and supply of raw materials and intermediates, and sales services.

 

The company has an office in Shanghai, leveraging the city's abundant market resources, information, international marketing networks, and advanced management concepts. Haiheng Biochemical Technology has entered a period of rapid development, with strong expansion momentum and significant growth potential. In the coming years, we will seize opportunities, strive diligently, and aim to build Haiheng Biochemical Technology into a nationally important production base for specialized active pharmaceutical ingredients and pharmaceutical intermediates.

 

Based on its robust R&D capabilities, market credibility, and sales network, the company has expanded its market to major global regions and has become a long-term raw material supplier for some of the world's leading pharmaceutical companies. The company's annual sales growth rate has consistently exceeded 40% for several years.

 

Adhering to the principles of "pragmatism, innovation, and integrity," the company will continue to provide customers with high-quality, competitively priced products and services, and sincerely hopes to establish stable strategic partnerships with outstanding enterprises both at home and abroad.